Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.

Shares in Eli Lilly were tracking down this morning after the company revealed data on its oral weight-loss candidate, orforglipron, that seems to have once again disappointed investors. The results ...